- Exchange: EN Paris
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for NicOx SA (COX)
| Open: | 2.9440 | Day's Range: | 2.8550 - 2.9840 | Volume: | 848,935 | Bid: | 2.9200 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 2.9400 | 52wk Range: | 0.7100 - 4.5200 | 1-Yr Rtn: | +71.99% | Ask: | 2.9290 |
Key Statistics for COX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E (12/2012) | - |
| Earnings Per Share (EUR) (ttm) | -0.2313 |
| Est. EPS (EUR) (12/2012) | -0.1040 |
| Est. PEG Ratio | - |
| Market Cap (M EUR) | 212.89 |
| Shares Outstanding (M) | 72.68 |
| Enterprise Value (M EUR) (ttm) | 128.95 |
| Enterprise Value/EBITDA (ttm) | - |
| Price/Book (mrq) | 2.5293 |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 07/30/2012 |
More COX Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for COX
- Operating
- Investing
- Financing (M/EUR)
Company Profile & Key Executives for COX
NicOx develops pharmaceuticals using recently discovered properties of nitric oxide. The Company develops drugs-candidates for the potential treatment of inflammatory, cardiometabolic and ophthalmological diseases. NicOx's lead compound naproxcinod is developed for the relief of the signs and symptoms of osteoarthritis.
| Michele GarufiChairman/CEO/Founder | Eric CastaldiChief Financial Officer |
| Pascal PfisterChief Scientific Officer | Philippe MasquidaExec VP/Mng Dir:European Ops |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page